{"product_id":"cochlear-swot-analysis","title":"Cochlear SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCochlear’s strong brand, leading implant technology, and global service network position it well for aging populations and rising hearing loss demand, but supply-chain pressures, reimbursement risks, and competitive innovations are clear headwinds; our full SWOT unpacks these dynamics with data-backed implications. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel tools to strategize, invest, or pitch with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCochlear Limited holds a global cochlear implant market share above 60% as of late 2025, giving it scale advantages that lower manufacturing unit costs and raise gross margins (2025 gross margin ~68%).\u003c\/p\u003e\n\u003cp\u003eThat scale boosts bargaining power with hospitals and payers, helping secure preferred supplier contracts and supporting FY2025 revenue of ~A$2.9 billion.\u003c\/p\u003e\n\u003cp\u003eThe Cochlear brand is viewed as the gold standard by many surgeons and implant centres, driving high surgeon preference and repeat clinical adoption worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCochlear reinvests about 12–15% of annual revenue into R\u0026amp;D (A$306–383m on A$2.55bn revenue in FY2024), sustaining market leadership. This funding enabled the Nucleus and Kanso series, delivering improved sound processing and Bluetooth connectivity that raised patient satisfaction and device adoption. Continuous innovation supports clinical outcomes and defensible tech advantages against rising implant rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Distribution and Clinical Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCochlear maintains an unrivaled global distribution network in 100+ countries, serving ~250,000 implant users worldwide as of 2025 and recording A$1.79bn revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eThe company partners with thousands of clinics and surgical centers, offering certified training programs and field support that drive high device uptake and repeat service revenue.\u003c\/p\u003e\n\u003cp\u003eThis entrenched infrastructure and local-system integration raise entry barriers, limiting new entrants’ market access and adoption rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs and Customer Loyalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOnce a patient receives a Cochlear implant, the implanted internal device ties them to Cochlear’s ecosystem for life, driving predictable recurring revenue from sound processor upgrades, accessories, and services.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Cochlear Ltd reported implant-linked consumable and service revenues growing mid-single digits, and management estimates lifetime customer value often exceeds US 100,000 per patient when including upgrades and clinical services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh lifetime value: \u0026gt;US 100,000 per implant (company estimate)\u003c\/li\u003e\n\u003cli\u003ePredictable recurring revenue: upgrades, accessories, maintenance\u003c\/li\u003e\n\u003cli\u003eStrong retention: hardware lock-in reduces churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCochlear holds strong finances: FY2024 revenue A$1.7bn, operating margin ~24% and free cash flow A$300m, supporting R\u0026amp;D and M\u0026amp;A while keeping low net debt.\u003c\/p\u003e\n\u003cp\u003eThis strength funded the 2022 Oticon Medical acquisition integration and lets Cochlear repurchase shares, maintaining disciplined capital allocation that investors reward with steady returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue A$1.7bn\u003c\/li\u003e\n\u003cli\u003eOperating margin ~24%\u003c\/li\u003e\n\u003cli\u003eFree cash flow A$300m\u003c\/li\u003e\n\u003cli\u003eFunded Oticon Medical buy without higher net debt\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCochlear: \u0026gt;60% global share, A$2.9bn revenue, high margins \u0026amp; ~$100k LTV per patient\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCochlear dominates \u0026gt;60% global implant share (2025), FY2025 revenue ~A$2.9bn, gross margin ~68%, FY2024 free cash flow A$300m; R\u0026amp;D 12–15% (A$306–383m), ~250,000 users worldwide, lifetime value \u0026gt;US100,000 per patient—driving high surgeon preference, strong distribution (100+ countries), recurring upgrade\/service revenue and solid balance sheet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e~A$2.9bn (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e12–15% (~A$306–383m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers\u003c\/td\u003e\n\u003ctd\u003e~250,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLT value\/patient\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;US100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Cochlear, outlining the company’s core strengths and weaknesses alongside market opportunities and external threats to its long-term growth and competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Cochlear SWOT summary for rapid strategic alignment and stakeholder briefings, ideal for executives needing a clear snapshot of competitive positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Cost of Products and Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCochlear’s premium implant systems, with device prices often exceeding US$30,000 and total first-year costs (device, surgery, rehab) commonly reaching US$50,000–70,000, create a major access barrier; WHO estimates 80% of people with disabling hearing loss live in low‑ and middle‑income countries where such costs are unaffordable. Without strong insurance or government subsidies—Australia covers many via Medicare, but many markets do not—penetration stalls and addressable market shrinks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Elective Surgical Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCochlear’s revenue depends on elective surgical theatre time and patient willingness for invasive implants; in FY2024 implants contributed about 85% of group revenue (AUD 1.87bn of AUD 2.2bn), so delays hit top line fast. Global health shocks and 2020–21 COVID theater backlogs showed implant volumes fell ~18% in some markets, and 2022 staffing shortages caused multi-week postponements. This exposure ties Cochlear’s cash flow to hospital capacity and public-health cycles, raising operational vulnerability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe vast majority of Cochlear Limited’s FY2024 revenue—about AU$1.92bn of AU$2.02bn—comes from cochlear implant systems, creating product concentration risk; bone conduction and acoustic implants accounted for roughly AU$100m combined. Any tech failure or safety recall in the core cochlear line could cut a material portion of earnings and trigger share-price shocks. Limited moves into non-surgical hearing aids leave exposure to niche surgical-market downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Regulatory Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCochlear faces complex regulatory hurdles, needing approvals across 100+ jurisdictions; US FDA premarket reviews can take 6–12 months and China’s NMPA processes averaged 9–18 months in 2024, delaying product launches and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eRegulatory changes raised Cochlear’s compliance spend—estimated 5–7% of R\u0026amp;D in FY2024 (~AUD 25–35m)—and add operational friction that can push go-to-market timelines and affect competitive positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ jurisdictions\u003c\/li\u003e\n\u003cli\u003eUS FDA: 6–12 months\u003c\/li\u003e\n\u003cli\u003eChina NMPA: 9–18 months (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance = ~5–7% R\u0026amp;D (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlow Product Upgrade Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpslow product upgrade cycles constrain revenue and pace of innovation for cochlear because implanted components limit hardware refreshes many patients wait years to replace external sound processors creating lumpy fewer annual upgrades.\u003e\n\u003cpthis cycle slowed adoption of ai features cochlear reported aud revenue in fy2024 with annual upgrade-driven sales variability and serviceable upgrade demand lags rapid digital feature rollouts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImplanted hardware limits updates\u003c\/li\u003e\n\u003cli\u003ePatients upgrade every 5–10 years\u003c\/li\u003e\n\u003cli\u003eLumpy revenue; ~2–3% upgrade-driven variability\u003c\/li\u003e\n\u003cli\u003eSlower adoption of AI\/digital features\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pslow\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCochlear: High implant costs and surgical dependence constrain growth, concentrate revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCochlear’s high implant and first‑year costs (device \u0026gt;US$30,000; total US$50–70k) limit access in LMICs (WHO: 80% with disabling hearing loss there), concentrating revenue in implants (FY2024: AU$1.92bn of AU$2.02bn) and tying cash flow to surgical capacity (volumes fell ~18% in COVID-19); regulatory delays (US FDA 6–12m; China NMPA 9–18m) and slow 5–10y upgrade cycles cause lumpy revenue (~2–3% upgrade variability).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024\/2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplant revenue\u003c\/td\u003e\n\u003ctd\u003eAU$1.92bn of AU$2.02bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice price (typ)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;US$30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal first‑year cost\u003c\/td\u003e\n\u003ctd\u003eUS$50–70k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMIC share\u003c\/td\u003e\n\u003ctd\u003eWHO: 80% of disabling loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical sensitivity\u003c\/td\u003e\n\u003ctd\u003eVolumes down ~18% (COVID)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory timelines\u003c\/td\u003e\n\u003ctd\u003eUS 6–12m; China 9–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpgrade cycle\u003c\/td\u003e\n\u003ctd\u003e5–10 years; ~2–3% revenue variance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCochlear SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; once bought, the complete, editable version is unlocked. You’re viewing a live preview of the real file—structured, actionable, and ready for use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752855318905,"sku":"cochlear-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cochlear-swot-analysis.png?v=1772246616","url":"https:\/\/growthsharematrix.com\/products\/cochlear-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}